Oral Migalastat HCl Leads to Greater Systemic Exposure and Tissue Levels of Active α-Galactosidase A in Fabry Patients when Co-Administered with Infused Agalsidase

Migalastat HCl (AT1001, 1-Deoxygalactonojirimycin) is an investigational pharmacological chaperone for the treatment of α-galactosidase A (α-Gal A) deficiency, which leads to Fabry disease, an X-linked, lysosomal storage disorder. The currently approved, biologics-based therapy for Fabry disease is...

Descripción completa

Detalles Bibliográficos
Autores principales: Warnock, David G., Bichet, Daniel G., Holida, Myrl, Goker-Alpan, Ozlem, Nicholls, Kathy, Thomas, Mark, Eyskens, Francois, Shankar, Suma, Adera, Mathews, Sitaraman, Sheela, Khanna, Richie, Flanagan, John J., Wustman, Brandon A., Barth, Jay, Barlow, Carrolee, Valenzano, Kenneth J., Lockhart, David J., Boudes, Pol, Johnson, Franklin K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4529213/
https://www.ncbi.nlm.nih.gov/pubmed/26252393
http://dx.doi.org/10.1371/journal.pone.0134341

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4529213/
https://www.ncbi.nlm.nih.gov/pubmed/26252393
http://dx.doi.org/10.1371/journal.pone.0134341

Ejemplares similares